Introduction

As the first monoclonal antibody to have been launched for a cancer indication, Herceptin demands attention. Because of the survival advantage it brings, it has been heralded as a breakthrough. However, it is still not used in every suitable breast cancer patient. 

Scope

Investigation of physician opinion to identify the barriers to the prescription of Herceptin 

Discussion of effective strategies to overcome the barriers to the prescription of Herceptin

Report Highlights

Herceptin offers significant improvements in survival rates, but is not always being prescribed to all appropriate patients. 

Reasons to Purchase

Plan new drug development to meet patient management requirements 

Explore the reasons, rational and emotional, behind cancer specialists' decisions 

Predict future trends and perception in the treatment of breast cancer patients 

Report Highlights

Product usage varies from country to country - reimbursement policies and company positioning within each geographic market impact uptake. 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a260